Compare JBHT & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBHT | ZBH |
|---|---|---|
| Founded | 1961 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 19.5B |
| IPO Year | 1994 | 2001 |
| Metric | JBHT | ZBH |
|---|---|---|
| Price | $213.56 | $94.00 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 19 |
| Target Price | ★ $198.33 | $105.17 |
| AVG Volume (30 Days) | 837.3K | ★ 2.2M |
| Earning Date | 04-16-2026 | 05-12-2026 |
| Dividend Yield | 0.80% | ★ 1.03% |
| EPS Growth | ★ 10.07 | N/A |
| EPS | ★ 6.12 | 3.55 |
| Revenue | $7,189,568,000.00 | ★ $8,231,500,000.00 |
| Revenue This Year | $5.27 | $4.93 |
| Revenue Next Year | $6.78 | $3.72 |
| P/E Ratio | $37.03 | ★ $26.28 |
| Revenue Growth | ★ 9.67 | 7.20 |
| 52 Week Low | $122.79 | $84.59 |
| 52 Week High | $236.00 | $114.44 |
| Indicator | JBHT | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 46.67 |
| Support Level | $212.47 | $93.29 |
| Resistance Level | $234.82 | $95.33 |
| Average True Range (ATR) | 7.18 | 2.18 |
| MACD | -1.46 | -0.72 |
| Stochastic Oscillator | 8.52 | 29.14 |
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.